19 November 2003 ASX / MEDIA ANNOUNCEMENT Peptech announces resolution to Abbott dispute Australian biotechnology company, Peptech Limited has reached an agreement in principle to resolve its recent dispute with Abbott Laboratories over its license arrangements for sales of HUMIRA®, a treatment for rheumatoid arthritis (RA). The confidential resolution is expected to be finalised in the coming weeks and is subject to final approval by both companies. Peptech Executive Chairman, Mr. Mel Bridges said he was delighted that a satisfactory business resolution to the patent dispute had been reached with the healthcare company. "With this dispute resolved, Peptech can refocus its strategy and now take advantage of a number of market opportunities," Mr. Bridges said. Background Abbott commenced selling HUMIRA® (adalimumab) in January this year after receiving marketing approval from the US Food and Drug Administration (FDA) in December 2002. Peptech focuses on the research and development of peptides and proteins in the areas of human pharmaceuticals and animal health. The company is positioning itself to become a globally recognized leader in biopharmaceutical development. Further information: Mr Mel Bridges Executive Chairman Peptech Limited Mobile: 0413 051 600 Suite 2, Level 3, Building A 11 Talavera Road (Locked Bag 2053) North Ryde NSW 2113 www.peptech.com ABN 98 002 951
PTD Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
